0 Items
Select Page

Campylobacter

Campylobacter is the most common cause of food poisoning in both the UK and United States, with the great majority of cases occurring from infected poultry.

Our Campylobacter product range includes monoclonal antibodies for both for research applications and immunoassay development.

Campylobacter Background

The bacterial genus Campylobacter are non-spore forming, curved, gram-negative bacteria of the family Campylobacteriacae. Over twenty-five species of Campylobacter have been identified but approximately 90% of human disease is caused by Campylobacter jejuni. Infectious disease caused by pathogenic Campylobacter species is referred to as Campylobacteriosis. Other species of Campylobacter causing Campylobacteriosis include C. coli, C. lari and C. upsaliensis but cases are less frequently reported.

Birds, including poultry, are major reservoirs of C. jejuni, where the bacteria survive in the intestines and crop of healthy birds. Most reported outbreaks of Campylobacteriosis have been associated with the consumption of undercooked poultry or poultry products. Symptoms of infection generally include fever, abdominal cramps, watery or haemorrhagic diarrhoea and weight loss. Although the disease is self-limiting, complications may develop in some cases after infection, which include irritable bowel syndrome, Guillain Barre syndrome and other autoimmune neuropathies (CDC).

Campylobacter Antibodies

Our anti-Campylobacter jejuni monoclonal antibodies are specific for the detection of Campylobacter jejuni species and can be used as a pair in the development of immunoassays.

Our antibodies do not cross react with Helicobacter pylori, Escherichia coli, Salmonella enteriditis, Salmonella paratyphi, Salmonella typhi, Salmonella typhimurium, Shigella boydii, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Yersinia enterocolitica, Listeria monocytogenes or Staphylococcus aureus.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Challenges to Effective Yellow Fever Diagnostics

Yellow fever is a haemorrhagic viral disease, transmitted by infected mosquitos in Africa and South America. While an effective vaccine is available, inadequate vaccination of endemic areas has made diagnostics a necessity to controlling ongoing outbreaks. However,...

Five Methods You Can Use to Overcome Zika-Dengue Cross-Reactivity

Cross-reactivity between the Zika and Dengue viruses in serological assays is one of the biggest challenges faced by the epidemiologists, academics and pharmaceutical companies trying to control the Zika epidemic, as it brings the quality and reliability of diagnostic...

Why Zika virus’s cross-reactivity with Dengue might be hampering your research

Given the impact of Zika, it’s no surprise that a global contingent of epidemiologists, academic researchers, and pharmaceutical companies are striving to develop effective disease control measures and treatments. One challenge currently hindering the...

How The Native Antigen Company responds to the WHO list of priority infectious diseases

In 2015, a broad group of public health and science experts gathered in Geneva to discuss emerging infectious diseases that are likely to cause future severe epidemics and public health emergencies. Organised by the World Health Organization (WHO), their aim was to...

Native Antigen release a panel of serotype specific monoclonal antibodies

  There are four distinct serotypes of Dengue Virus circulating around the world, causing Dengue fever infection which is the most important worldwide arboviral disease. There are nearly 400 million cases of Dengue annually, and around 25% present with so called...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

11 + 3 =

Live Customer Feedback